Cargando…
Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application
AIM OF THE STUDY: To establish and evaluate the fingerprint diagnostic models of cerebrospinal protein profile in glioma with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and bioinformatics analysis, in order to seek new tumor markers. MATERIAL AND MET...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068817/ https://www.ncbi.nlm.nih.gov/pubmed/24966792 http://dx.doi.org/10.5114/wo.2014.40455 |
_version_ | 1782322461543497728 |
---|---|
author | Liu, Jian Yu, Jiekai Shen, Hong Zhang, Jianmin Liu, Weiguo Chen, Zhe He, Shuda Zheng, Shu |
author_facet | Liu, Jian Yu, Jiekai Shen, Hong Zhang, Jianmin Liu, Weiguo Chen, Zhe He, Shuda Zheng, Shu |
author_sort | Liu, Jian |
collection | PubMed |
description | AIM OF THE STUDY: To establish and evaluate the fingerprint diagnostic models of cerebrospinal protein profile in glioma with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and bioinformatics analysis, in order to seek new tumor markers. MATERIAL AND METHODS: SELDI-TOF-MS was used to detect the cerebrospinal protein bond to ProteinChip H4. The cerebrospinal protein profiles were obtained and analyzed using the artificial neural network (ANN) method. Fingerprint diagnostic models of cerebrospinal protein profiles for distinguishing glioma from non-brain-tumor, and distinguishing glioma from benign brain tumor, were established. The support vector machine (SVM) algorithm was used for verification of established diagnostic models. The tumor markers were screened. RESULTS: In a fingerprint diagnostic model of cerebrospinal protein profiles for distinguishing glioma from non-brain tumor, the sensitivity and specificity of glioma diagnosis were 100% and 91.7%, respectively. Seven candidate tumor markers were obtained. In a fingerprint diagnostic model for distinguishing glioma from benign brain tumor, the sensitivity and specificity of glioma diagnosis were 88.9% and 100%, respectively, and 8 candidate tumor markers were gained. CONCLUSIONS: The combination of SELDI-TOF-MS and bioinformatics tools is a very effective method for screening and identifying new markers of glioma. The established diagnostic models have provided a new way for clinical diagnosis of glioma, especially for qualitative diagnosis. |
format | Online Article Text |
id | pubmed-4068817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-40688172014-06-25 Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application Liu, Jian Yu, Jiekai Shen, Hong Zhang, Jianmin Liu, Weiguo Chen, Zhe He, Shuda Zheng, Shu Contemp Oncol (Pozn) Original Paper AIM OF THE STUDY: To establish and evaluate the fingerprint diagnostic models of cerebrospinal protein profile in glioma with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and bioinformatics analysis, in order to seek new tumor markers. MATERIAL AND METHODS: SELDI-TOF-MS was used to detect the cerebrospinal protein bond to ProteinChip H4. The cerebrospinal protein profiles were obtained and analyzed using the artificial neural network (ANN) method. Fingerprint diagnostic models of cerebrospinal protein profiles for distinguishing glioma from non-brain-tumor, and distinguishing glioma from benign brain tumor, were established. The support vector machine (SVM) algorithm was used for verification of established diagnostic models. The tumor markers were screened. RESULTS: In a fingerprint diagnostic model of cerebrospinal protein profiles for distinguishing glioma from non-brain tumor, the sensitivity and specificity of glioma diagnosis were 100% and 91.7%, respectively. Seven candidate tumor markers were obtained. In a fingerprint diagnostic model for distinguishing glioma from benign brain tumor, the sensitivity and specificity of glioma diagnosis were 88.9% and 100%, respectively, and 8 candidate tumor markers were gained. CONCLUSIONS: The combination of SELDI-TOF-MS and bioinformatics tools is a very effective method for screening and identifying new markers of glioma. The established diagnostic models have provided a new way for clinical diagnosis of glioma, especially for qualitative diagnosis. Termedia Publishing House 2014-06-03 2014 /pmc/articles/PMC4068817/ /pubmed/24966792 http://dx.doi.org/10.5114/wo.2014.40455 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Paper Liu, Jian Yu, Jiekai Shen, Hong Zhang, Jianmin Liu, Weiguo Chen, Zhe He, Shuda Zheng, Shu Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application |
title | Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application |
title_full | Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application |
title_fullStr | Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application |
title_full_unstemmed | Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application |
title_short | Mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application |
title_sort | mass spectrometric analysis of cerebrospinal fluid protein for glioma and its clinical application |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068817/ https://www.ncbi.nlm.nih.gov/pubmed/24966792 http://dx.doi.org/10.5114/wo.2014.40455 |
work_keys_str_mv | AT liujian massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication AT yujiekai massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication AT shenhong massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication AT zhangjianmin massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication AT liuweiguo massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication AT chenzhe massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication AT heshuda massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication AT zhengshu massspectrometricanalysisofcerebrospinalfluidproteinforgliomaanditsclinicalapplication |